Inhibition of both KDM3A and KDM4B provide a greater effect on ER activity and cell growth, which may be an effective strategy for treating ER-driven BC (Mahajan et al., 2014; Wade et al., 2015; Jones et al., 2019). Here, KDM3A is linked to breast cancer.